Cooper Co (COO) AI Stock Analysis

• Market Cap: $16.58B
• Dividend Yield: N/A
• Average Volume (3M): 1.88M
• Price to Earnings (P/E): 40.1
• Beta (1Y): 0.86
• Revenue Growth: 7.15%
• EPS Growth: 41.96%
• Country: US
• Employees: 16,000
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.92
• Shares Outstanding: 199,981,190
• 10 Day Avg. Volume: 1,792,362
• 30 Day Avg. Volume: 1,877,284
• PEG Ratio: 7.14
• Price to Book (P/B): 2.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 42.77
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 1.23
• Enterprise Value/Gross Profit: 7.46
• Enterprise Value/Ebitda: 4.76
• 1Y Price Target: $108.56
• Price Target Upside: 30.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

Cooper Co's overall stock score reflects its strong financial performance and positive earnings outlook, tempered by technical and valuation concerns. The company's robust growth trajectory and strategic initiatives are promising, but potential overvaluation and mixed technical signals suggest caution in the short term.

Positive Factors

Market Resilience

The contact lens market, where Cooper Companies operates, is considered recession resilient as patients prioritize their vision needs.

Supply and Capacity

Cooper Companies is expected to benefit from increased supply, which should help it achieve its growth targets despite a challenging start to the fiscal year.

Negative Factors

Market Slowdowns

Recent checks indicate incremental slowdowns in the market, prompting a reduction in forecasted earnings and revenue for the upcoming quarter.

Valuation Gap

There is a significant valuation gap with a 30% discount for COO compared to ALC, reflecting priced-in fundamental risks.

Cooper Co Business Overview & Revenue Model

Company Description

Cooper Co (COO) is a leading global provider of medical devices that cater primarily to the healthcare industry. The company operates in several sectors, including ophthalmic instruments and women's health, with a focus on designing, manufacturing, and distributing high-quality products. Its core products include contact lenses and diagnostic equipment, which are utilized by healthcare professionals worldwide to enhance patient care and improve health outcomes.

How the Company Makes Money

Cooper Co makes money primarily through the sale of its medical devices, particularly contact lenses and diagnostic equipment. The company generates revenue from direct sales to healthcare providers, clinics, and optical retailers. Additionally, Cooper Co benefits from long-term contracts and partnerships with hospitals and healthcare systems, which provide a steady stream of income. The company also invests in research and development to innovate and expand its product offerings, creating new revenue opportunities. Cooper Co's global distribution network and strong brand reputation further enhance its ability to capture market share and drive sales growth.

Cooper Co Financial Statement Overview

Summary

Cooper Co exhibits a robust financial position with strong revenue growth, efficient operations, and a solid equity base. The company maintains healthy margins and profitability, supported by effective cash flow management. While debt levels and capital expenditures warrant attention, the overall financial health of Cooper Co positions it well within the Medical Equipment & Supplies industry.

Income Statement

Cooper Co has demonstrated strong revenue growth, with a positive trajectory from $2.43 billion in 2020 to $3.93 billion in TTM 2025. The gross profit margin remains robust, averaging above 60%, and the EBIT and EBITDA margins indicate healthy operational efficiency. Net profit margin is stable and shows consistent profitability. Overall, the company reflects strong growth and profit stability in the income statement.

Balance Sheet

The balance sheet of Cooper Co shows a solid equity position with a debt-to-equity ratio that is healthy for the industry, indicating manageable leverage. The equity ratio demonstrates a strong asset base supported by equity. Return on Equity (ROE) is positive, reflecting efficient use of equity to generate profits. However, total debt has increased slightly, which may require monitoring.

Cash Flow

Cooper Co's cash flow statement reveals consistent free cash flow generation, albeit modest growth. Operating cash flow is strong relative to net income, indicating good cash generation from operations. However, free cash flow growth is limited by capital expenditures and fluctuations in investing cash flow. Overall, cash flow is stable but may benefit from enhanced free cash flow growth.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.93B	3.90B	3.59B	3.31B	2.92B	2.43B
	Gross Profit
2.53B	2.60B	2.36B	2.14B	1.96B	1.53B
	EBIT
734.60M	705.70M	533.10M	507.60M	505.80M	311.80M
	EBITDA
932.40M	705.70M	885.90M	908.60M	863.70M	622.90M
	Net Income Common Stockholders
415.40M	392.30M	294.20M	385.80M	2.94B	238.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
107.60M	107.60M	120.90M	138.20M	95.90M	115.90M
	Total Assets
12.32B	12.32B	11.66B	11.49B	9.61B	6.74B
	Total Debt
2.58B	2.58B	2.57B	2.76B	1.71B	2.03B
	Net Debt
2.48B	2.48B	2.45B	2.63B	1.61B	1.91B
	Total Liabilities
4.23B	4.23B	4.11B	4.32B	2.66B	2.91B
	Stockholders Equity
8.08B	8.08B	7.55B	7.17B	6.94B	3.82B
Cash Flow		Free Cash Flow
384.70M	288.10M	215.00M	450.40M	524.20M	176.20M
	Operating Cash Flow
777.20M	709.30M	607.50M	692.40M	738.60M	486.60M
	Investing Cash Flow
-537.30M	-764.60M	-449.00M	-1.83B	-450.30M	-364.50M
	Financing Cash Flow
-269.70M	39.20M	-173.90M	1.19B	-311.40M	-95.50M

Cooper Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 82.92
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Positive. The current price of 82.92 is above the 20-day moving average (MA) of 81.58, above the 50-day MA of 80.53, and below the 200-day MA of 94.42, indicating a neutral trend. The MACD of 0.39 indicates Negative momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 42.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COO.

Cooper Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATR	78 Outperform	$10.37B	28.71	15.15%	1.12%	0.34%	17.27%
WST	74 Outperform	$15.56B	34.02	17.42%	0.38%	-1.14%	-16.35%
COO	74 Outperform	$16.58B	40.10	5.25%	―	7.15%	41.96%
HOLX	66 Neutral	$12.66B	23.98	11.77%	―	1.66%	21.95%
MASI	58 Neutral	$8.44B	116.65	-23.93%	―	-0.12%	-713.82%
BAX	56 Neutral	$16.25B	136.07	-8.96%	2.90%	-20.17%	-138.32%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%

Cooper Co Corporate Events

Cooper Co Appoints Barbara Carbone to Board

CooperCompanies announced the appointment of Barbara Carbone as an independent director to its Board of Directors, effective May 1, 2025. Ms. Carbone, who brings nearly four decades of experience, primarily from her tenure at KPMG LLP, will also join the Audit Committee. Her extensive expertise in financial and accounting matters, along with leadership skills, is expected to contribute significantly to the company’s governance and strategic direction.

Spark’s Take on COO Stock

According to Spark, TipRanks’ AI Analyst, COO is a Outperform.

Cooper Co’s stock is well-supported by solid financial performance and positive earnings call guidance, indicating strong operational execution. However, technical indicators suggest bearish trends, and valuation metrics point to potential overvaluation. Overall, while the company is fundamentally strong, the stock may face short-term pressure due to technical and valuation concerns.

To see Spark’s full report on COO stock, click here.